A Study of MORAb-202 in Participants With Previously Treated Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC)
Terminated · Phase 2 · NCT05577715
Conditions: Carcinoma, Non-Small-Cell Lung
At a glance
- Research payments reported, 2025
- $9,350
- U.S. investigators named
- 6
- Sites paid
- 5
- Planned or actual enrollment
- 31
About the trial
- Sponsor
- Bristol-Myers Squibb (with Eisai Inc.)
- Tested
- MORAb-202 (drug)
- Dates
- Started 2022-11-14; completion 2024-08-12
- Results posted
- Yes
The aim of this study is to characterize the safety and tolerability of MORAb-202, and to assess the objective response rate in participants with previously treated, metastatic NSCLC AC.
From ClinicalTrials.gov, last updated 2025-09-04. Full record, eligibility and contacts (opens in a new tab)
Industry funding
E.r. Squibb & Sons, L.l.c. reported $9,350 in research payments for this study in 2025 (10 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Robert M. Jotte, MD Hematology & Oncology · Lone Tree, CO
- Makenzi C. Evangelist, M.D. Hematology & Oncology · Albany, NY
- John W. Adams, DO Medical Oncology · Arlington, TX
- Enrique A. Perez, MD Medical Oncology · Carrollton, TX
- Vinni Juneja, MD Hematology & Oncology · Alexandria, VA
- Alexander I. Spira, M.D. Medical Oncology · Fairfax, VA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Texas Onco Southwest Fort Worth $3,740
- Rocky Mountain Cancer Centers LLP $1,870
- Maryland Oncology Hematology, PA $1,870
- Virginia Cancer Specialists, PC $935
- New York Oncology Hematology, PC $935
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.